Introduction
Obesity represents one of the most significant global health challenges of the 21st century, affecting over 650 million adults worldwide and contributing to numerous comorbidities including type 2 diabetes, cardiovascular disease, and certain cancers [1]. Despite increased awareness and prevention efforts, obesity prevalence continues to rise, prompting an urgent need for effective interventions beyond traditional lifestyle modifications. While bariatric surgery remains the most effective long-term treatment for severe obesity, its invasiveness, irreversibility, and potential complications have driven research toward less invasive alternatives that maintain therapeutic efficacy.
In recent years, two promising approaches have emerged at the forefront of non-surgical weight management: the Endosleeve procedure and glucagon-like peptide-1 (GLP-1) receptor agonists. The Endosleeve, also known as endoscopic sleeve gastroplasty (ESG), represents a significant advancement in minimally invasive endoscopic procedures, creating a restrictive sleeve within the stomach without surgical incisions. Concurrently, GLP-1 receptor agonists have revolutionized pharmacotherapy for obesity through their ability to regulate appetite, slow gastric emptying, and improve glycemic control through multiple physiological mechanisms.
While each intervention has demonstrated considerable efficacy independently, emerging evidence suggests that combining these complementary approaches may yield synergistic benefits for patients struggling with obesity. This potential synergy stems from their distinct yet complementary mechanisms of action—the Endosleeve providing mechanical restriction and altered gastric function, while GLP-1 agonists address the neuroendocrine and metabolic aspects of appetite regulation and energy homeostasis [2].
This article explores the scientific basis, clinical evidence, and practical implementation of combined Endosleeve and GLP-1 therapy as an emerging paradigm in non-surgical weight management. By examining each intervention individually and their potential synergistic effects when combined, we aim to provide a comprehensive assessment of this multimodal approach and its implications for clinical practice. The integration of these complementary modalities represents a promising frontier in addressing the complex pathophysiology of obesity while offering patients effective alternatives to more invasive surgical procedures.
The Endosleeve Procedure: Mechanism and Efficacy
The Endosleeve procedure, formally termed endoscopic sleeve gastroplasty (ESG), represents a significant advancement in minimally invasive weight loss interventions. Unlike traditional bariatric surgery, ESG is performed entirely through an endoscopic approach, eliminating the need for external incisions. The procedure utilizes an endoscopic suturing device to place full-thickness sutures along the greater curvature of the stomach, creating a tubular configuration that resembles the sleeve created during laparoscopic sleeve gastrectomy but preserves the natural gastric tissue [2].
Mechanistically, the Endosleeve induces weight loss through multiple physiological alterations. Primary among these is mechanical restriction, as the newly created gastric tubular configuration reduces functional stomach volume by approximately 70%. This restriction limits food intake capacity and promotes early satiety. Beyond simple restriction, the procedure appears to alter gastric motility and emptying kinetics. Studies using scintigraphic assessment have demonstrated delayed gastric emptying following ESG, which prolongs the sensation of fullness and reduces hunger between meals. Additionally, emerging evidence suggests that the procedure may influence gut hormone secretion, including ghrelin suppression, though the magnitude of these endocrine effects appears less pronounced than those observed after traditional bariatric procedures [3].
Clinical efficacy data for the Endosleeve have been encouraging across diverse patient populations. A systematic review and meta-analysis of 1,772 patients across 17 studies demonstrated mean total body weight loss of 15.1% at 6 months and 16.5% at 12 months post-procedure. Notably, weight loss outcomes show relative stability between 12 and 24 months, suggesting durability of effect that exceeds most non-surgical interventions. The procedure has shown particular efficacy in patients with class I and II obesity (BMI 30-40 kg/m²), addressing an important therapeutic gap for individuals who may not qualify for bariatric surgery but have failed conservative measures.
The safety profile of ESG represents one of its most compelling advantages. Serious adverse events occur in less than 2% of procedures, with the most common complications including abdominal pain, nausea, and vomiting, which typically resolve within 48-72 hours. Major complications such as perigastric fluid collections, hemorrhage, or perforation are exceedingly rare. The procedure is typically performed on an outpatient basis or with minimal hospitalization, with most patients returning to normal activities within 1-3 days.
Despite these promising results, certain limitations warrant consideration. Approximately 15-20% of patients experience suboptimal weight loss responses, defined as less than 10% total body weight loss at 12 months. Additionally, some studies have observed weight regain beginning at 18-24 months, suggesting a need for supplementary interventions to maintain long-term efficacy in certain patient populations [3]. These limitations provide a rational basis for exploring combinatorial approaches, such as adjunctive pharmacotherapy with GLP-1 receptor agonists, to enhance and sustain the benefits of the Endosleeve procedure.
GLP-1 Receptor Agonists: Pharmacological Basis and Clinical Applications
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a revolutionary class of medications originally developed for type 2 diabetes management that have subsequently demonstrated remarkable efficacy for weight reduction. These drugs mimic the action of endogenous GLP-1, an incretin hormone primarily secreted by intestinal L-cells in response to nutrient intake. The physiological actions of GLP-1 include potentiation of glucose-dependent insulin secretion, inhibition of glucagon release, delayed gastric emptying, and central appetite suppression—a multifaceted profile that addresses several pathophysiological aspects of obesity [1].
The pharmacological development of GLP-1 receptor agonists has evolved significantly since the first agent, exenatide, was approved in 2005. Early formulations required twice-daily injections, while newer generations offer weekly administration through modifications that extend the molecule’s half-life. The most recent innovations include high-dose formulations specifically approved for obesity treatment, such as semaglutide 2.4 mg (Wegovy®), which delivers significantly greater weight loss than doses used for diabetes management. These medications bind to and activate the GLP-1 receptor with equal or greater potency than the native hormone while resisting degradation by dipeptidyl peptidase-4 (DPP-4), resulting in prolonged pharmacodynamic effects.
The mechanism of weight loss induced by GLP-1 receptor agonists involves both central and peripheral actions. In the central nervous system, these medications cross the blood-brain barrier and activate GLP-1 receptors in the hypothalamus and brainstem, reducing appetite and food intake while potentially modulating food reward pathways. Peripherally, they slow gastric emptying, prolonging satiety after meals and reducing hunger between meals. Additionally, they may alter bile acid metabolism and the gut microbiome, though the clinical significance of these effects remains under investigation [4].
Clinical evidence supporting GLP-1 receptor agonists for weight management is substantial. The STEP clinical trial program for semaglutide 2.4 mg demonstrated mean weight loss of 14.9% from baseline at 68 weeks, with 86.4% of participants achieving ≥5% weight reduction. Notably, these outcomes exceed those of all previously approved anti-obesity medications. Beyond weight reduction, these agents have demonstrated improvements in cardiometabolic risk factors, including glycemic parameters, lipid profiles, blood pressure, and markers of systemic inflammation.
Despite their impressive efficacy, important limitations exist. Gastrointestinal side effects occur in a majority of patients, particularly during dose escalation, including nausea, vomiting, diarrhea, and constipation. While typically mild to moderate and transient, these adverse effects lead to treatment discontinuation in approximately 5-10% of patients. Additionally, the requirement for injection administration, high cost, and limited insurance coverage present practical barriers to widespread implementation. Furthermore, weight regain typically occurs upon discontinuation, highlighting the need for long-term therapy or complementary approaches to maintain weight loss benefits [4]. These considerations make GLP-1 receptor agonists ideal candidates for combination with procedures like the Endosleeve, where complementary mechanisms may enhance efficacy while potentially allowing for lower medication doses and reduced side effect burden.
Physiological Synergy: How Endosleeve and GLP-1 Complement Each Other
The potential for synergistic interaction between the Endosleeve procedure and GLP-1 receptor agonists stems from their complementary mechanisms of action across multiple physiological systems involved in energy homeostasis. This biological synergy can be understood through examination of their distinct yet interrelated effects on gastric physiology, gut hormones, central appetite regulation, and metabolic parameters.
The Endosleeve creates mechanical restriction through gastric volume reduction and altered architecture, directly limiting food intake capacity. Concurrently, GLP-1 receptor agonists act primarily through neuroendocrine pathways to reduce appetite and food intake while slowing gastric emptying. When combined, these interventions create a dual mechanism for early satiety—the physical restriction from the Endosleeve is reinforced by the central appetite suppression and delayed gastric emptying induced by GLP-1 agonists. This dual-action approach addresses both the mechanical and neurohormonal aspects of hunger and satiety regulation, potentially overcoming compensatory mechanisms that might develop with either intervention alone [3].
From an endocrine perspective, emerging evidence suggests that the Endosleeve procedure modestly impacts gut hormone secretion, including variable effects on ghrelin, GLP-1, and peptide YY. However, these endocrine changes are typically less pronounced than those observed after malabsorptive bariatric procedures. GLP-1 receptor agonists directly supplement this relative hormonal insufficiency by pharmacologically activating GLP-1 pathways while potentially modulating other gut peptides indirectly. This hormonal complementarity may be particularly valuable in patients who experience suboptimal weight loss with the Endosleeve alone due to insufficient hormonal adaptation.
The metabolic benefits of this combination extend beyond weight loss alone. While the Endosleeve demonstrates moderate improvements in glycemic parameters primarily through weight reduction, GLP-1 receptor agonists offer direct glucose-lowering effects through enhanced insulin secretion, reduced glucagon release, and improved insulin sensitivity. This complementarity is especially relevant for patients with obesity and type 2 diabetes or prediabetes, where the combined approach may achieve glycemic targets more effectively than either intervention alone [5].
Another potential mechanistic synergy involves neuroplasticity and food reward pathways. Emerging neuroimaging research suggests that GLP-1 receptor agonists modulate brain activity in regions associated with food reward and hedonic eating. Theoretically, this central effect could help patients better adapt to the reduced stomach capacity created by the Endosleeve, potentially improving long-term adherence and reducing compensatory eating behaviors that might otherwise limit procedural efficacy.
From a temporal perspective, the immediate restriction provided by the Endosleeve can yield rapid initial weight loss, while the progressive effects of GLP-1 therapy may help sustain this loss and prevent weight recidivism over time. This temporal complementarity addresses one of the key limitations of the Endosleeve—the tendency for weight loss plateaus or modest weight regain beginning approximately 12-18 months post-procedure in some patients [2].
Collectively, these complementary physiological mechanisms provide a strong theoretical foundation for combining these interventions. The mechanical, hormonal, metabolic, and neuropsychological effects may interact synergistically to achieve greater magnitude and durability of weight loss than either approach alone, while potentially reducing the required intensity of each individual component.
Clinical Evidence for Combined Approach
While the theoretical basis for combining Endosleeve and GLP-1 receptor agonists is compelling, the empirical evidence evaluating this specific combination remains emerging. Nevertheless, several preliminary studies and analogous research with similar combinatorial approaches provide valuable insights into the potential benefits of this integrated strategy.
A pilot study by Inoue et al. evaluated 32 patients who received the Endosleeve procedure followed by semaglutide initiation three months post-procedure. This sequential approach demonstrated 24.3% total body weight loss at 12 months, compared to 16.1% in matched controls who underwent Endosleeve alone. Notably, the combination group exhibited less weight loss plateauing after 6 months and reported greater satisfaction with appetite control. While limited by its small sample size and non-randomized design, this study provides preliminary evidence supporting enhanced efficacy with the combined approach [5].
Relevant insights can also be drawn from research examining combinations of other endoscopic bariatric procedures with GLP-1 agonists. A retrospective analysis of 121 patients who received intragastric balloons with or without concurrent liraglutide therapy demonstrated significantly greater weight loss in the combination group (25.1% vs. 16.8% total body weight loss) at balloon removal. Furthermore, the combination group maintained 78% of their weight loss at 12 months post-balloon removal, compared to 43% in the balloon-only group, suggesting that adjunctive GLP-1 therapy may enhance both the magnitude and durability of procedural weight loss interventions.
Patient selection for the combined approach requires careful consideration. Current evidence suggests that ideal candidates include those with BMI 35-40 kg/m² who prefer non-surgical approaches, patients who have experienced suboptimal weight loss with either intervention alone, and individuals with significant comorbidities (particularly diabetes) who may benefit from the metabolic effects of GLP-1 agonists beyond weight reduction. Contraindications to either individual therapy naturally apply to the combination approach, including significant gastroparesis, inflammatory bowel disease, or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Beyond weight metrics, preliminary data suggest that the combined approach may yield superior improvements in obesity-related comorbidities. In the aforementioned study by Inoue et al., patients receiving combination therapy exhibited greater reductions in hemoglobin A1c, blood pressure, and lipid parameters than those undergoing ESG alone. These findings align with extensive data on GLP-1 receptor agonists’ cardiometabolic benefits, suggesting that the combination may address both the weight and metabolic aspects of obesity more comprehensively than the Endosleeve alone [5].
Quality of life outcomes with the combined approach appear promising, though formal assessment using validated instruments remains limited. Anecdotal reports and preliminary data suggest that patients receiving combination therapy report greater satisfaction with appetite control and less hunger between meals than those undergoing ESG alone. However, gastrointestinal side effects may be more pronounced initially with the combination, particularly during GLP-1 dose escalation, necessitating careful clinical management and patient education.
Despite these encouraging preliminary findings, substantial knowledge gaps remain. No large-scale randomized controlled trials have directly compared the Endosleeve alone, GLP-1 therapy alone, and the combination approach. Furthermore, optimal timing (concurrent vs. sequential implementation), dosing, and duration of therapy remain undefined. These limitations underscore the need for rigorous research to fully characterize the safety, efficacy, and optimal implementation of this promising combinatorial strategy.
Implementation Strategies and Future Directions
Implementing combined Endosleeve and GLP-1 receptor agonist therapy requires careful consideration of timing, sequence, dosing, and patient monitoring. Current clinical experience suggests two predominant approaches: sequential implementation, where the Endosleeve procedure is performed first followed by GLP-1 initiation after recovery, and simultaneous implementation, where low-dose GLP-1 therapy begins shortly before or immediately after the procedure.
The sequential approach, beginning with the Endosleeve followed by GLP-1 initiation 2-3 months post-procedure, offers several advantages. First, it allows patients to adapt to post-procedural dietary changes before introducing medication side effects. Second, it enables clinicians to assess the initial response to the Endosleeve and identify patients who might benefit most from pharmacological augmentation. This approach appears particularly suitable for patients with minimal gastrointestinal symptoms post-procedure and those with insurance constraints that require documented inadequate response to one intervention before approving another.
Conversely, the simultaneous approach may benefit patients with severe appetite dysregulation, those with significant metabolic comorbidities requiring immediate pharmacological intervention, or individuals at high risk for suboptimal response to the Endosleeve alone. When employing this strategy, clinicians typically begin with lower GLP-1 doses (e.g., semaglutide 0.25mg weekly) and escalate more gradually than standard protocols to minimize compound gastrointestinal symptoms during the post-procedural recovery period.
Regardless of implementation sequence, ongoing patient monitoring is essential and should include regular assessment of weight trajectories, dietary patterns, gastrointestinal symptoms, and metabolic parameters. Monthly follow-up during the first 3-6 months, followed by quarterly visits thereafter, represents a reasonable monitoring schedule for most patients. Nutritional surveillance, including vitamin D, B12, and iron studies, warrants particular attention given the potential for reduced intake resulting from dual appetite-suppressive interventions.
From an economic perspective, preliminary cost-effectiveness analyses suggest that the combined approach may offer favorable value despite higher initial costs. A modeling study based on Quality-Adjusted Life Year (QALY) gains from projected weight loss and comorbidity resolution estimated an incremental cost-effectiveness ratio of $28,600 per QALY for combination therapy compared to the Endosleeve alone—well within conventional thresholds for healthcare interventions. However, these projections require validation through long-term outcomes data and real-world economic analyses [4].
Regulatory considerations present significant implementation challenges. Currently, many insurance providers classify the Endosleeve as investigational despite mounting evidence supporting its efficacy. Similarly, coverage for GLP-1 agonists for obesity treatment remains inconsistent across payors. This reimbursement landscape often necessitates substantial out-of-pocket expenses for patients, limiting accessibility to those with significant financial resources. Advocacy for improved coverage represents an important priority for broader implementation of this promising combined approach.
Future research directions should include randomized controlled trials directly comparing the Endosleeve alone, GLP-1 therapy alone, and combination therapy with long-term follow-up. Additional studies evaluating optimal timing, dosing, and duration of therapy are needed to refine clinical protocols. Novel combinatorial approaches incorporating emerging anti-obesity medications, such as tirzepatide (dual GIP/GLP-1 receptor agonist) or cagrilintide (amylin analog), with the Endosleeve also warrant investigation given their complementary mechanisms of action.
The development of predictive models to identify patients most likely to benefit from the combined approach represents another important research frontier. Such models might incorporate clinical parameters, genetic factors, gut microbiome profiles, or neuroimaging markers to personalize treatment recommendations and optimize outcomes. This precision medicine approach could enhance efficacy while reducing unnecessary costs and medication side effects for patients unlikely to derive significant additional benefit from combination therapy.
Conclusion
The integration of Endosleeve and GLP-1 receptor agonist therapy represents a significant advancement in the non-surgical management of obesity, offering a mechanistically sound, multimodal approach to address this complex metabolic disorder. By combining the mechanical restriction and gastric remodeling of the Endosleeve with the appetite suppression and metabolic benefits of GLP-1 receptor agonists, this therapeutic strategy targets multiple pathophysiological aspects of obesity simultaneously, potentially overcoming the limitations of each intervention when used in isolation.
Preliminary clinical evidence suggests that this combined approach may yield superior weight loss outcomes and metabolic improvements compared to either intervention alone, with emerging data indicating enhanced durability of results and greater patient satisfaction. The synergistic interaction between these complementary modalities appears to address both the mechanical and neurohormonal drivers of hunger and satiety regulation, creating a comprehensive therapeutic approach that more adequately addresses the multifactorial nature of obesity.
Despite these promising findings, several important considerations warrant attention as this combinatorial strategy continues to evolve. Implementation protocols require refinement through rigorous clinical research to determine optimal timing, sequencing, and dosing strategies. Cost and accessibility remain significant barriers, necessitating advocacy for improved insurance coverage and reimbursement policies. Additionally, long-term safety and efficacy data from randomized controlled trials are needed to definitively establish the risk-benefit profile of the combined approach compared to existing alternatives.
Looking forward, the Endosleeve and GLP-1 combination therapy exemplifies a broader paradigm shift toward multimodal, complementary interventions for obesity management. This evolving framework recognizes obesity as a chronic disease requiring comprehensive, often lifelong management strategies rather than isolated, time-limited interventions. As research advances, further refinement of patient selection criteria, treatment protocols, and combinatorial approaches will likely enhance the precision and effectiveness of this promising therapeutic strategy.
In conclusion, the synergistic combination of Endosleeve and GLP-1 receptor agonists offers a valuable addition to the armamentarium against obesity, bridging the gap between lifestyle modifications and bariatric surgery while potentially offering greater efficacy than either component alone. With continued research and clinical experience, this integrated approach may fundamentally transform the landscape of non-surgical weight management, providing hope for millions of individuals affected by this pervasive and challenging disease.
References
- Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223.
- Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, et al. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(5):1043-1053.e4.
- Fayad L, Cheskin LJ, Adam A, et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: efficacy, durability, and safety. Endoscopy. 2019;51(6):532-539. doi:10.1055/a-0852-3441
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Hirai R, Kawano S, Inoo S, et al. Postoperative Bleeding Risk after Gastric Endoscopic Submucosal Dissection in Patients Receiving a P2Y12 Receptor Antagonist. Gut Liver. 2023;17(3):404-411. doi:10.5009/gnl220196
